Stephen J. Hill - 16 Jun 2021 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Technical Ops. Officer
Signature
/s/ Heather Turner, as Attorney-in-fact
Issuer symbol
LYEL
Transactions as of
16 Jun 2021
Net transactions value
$0
Form type
3
Filing time
16 Jun 2021, 19:15:57 UTC
Next filing
18 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LYEL Option (right to buy) 16 Jun 2021 Common Stock 500,000 $3.65 Direct F1
holding LYEL Option (right to buy) 16 Jun 2021 Common Stock 165,000 $3.65 Direct F2
holding LYEL Option (right to buy) 16 Jun 2021 Common Stock 450,000 $5.96 Direct F3
holding LYEL Option (right to buy) 16 Jun 2021 Common Stock 100,000 $6.24 Direct F4
holding LYEL Option (right to buy) 16 Jun 2021 Common Stock 85,000 $12.67 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares vested on June 19, 2020, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.
F2 The shares vest in equal monthly installments over the forty-eight months following February 1, 2020.
F3 The shares vest in equal monthly installments over the forty-eight months following December 1, 2020.
F4 The shares vest in equal monthly installments over the forty-eight months following March 1, 2021.
F5 The shares vest in equal monthly installments over the forty-eight months following April 14, 2021.